Pozelimab: First Approval

Protein-Losing Enteropathy

(2023) Ahmet Ozen et al.   NEW ENGLAND JOURNAL OF MEDICINE

P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB

(2023) Richard Kelly et al.   HemaSphere

P782: A PHASE 2, RANDOMIZED TRIAL EVALUATING THE SAFETY AND EFFICACY OF POZELIMAB AND CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

(2023) Jun-Ho Jang et al.   HemaSphere

P775: LONG-TERM EFFICACY AND SAFETY OF POZELIMAB MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

(2023) Jun-Ho Jang et al.   HemaSphere

Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease

(2021) Ahmet Ozen et al.   NATURE IMMUNOLOGY

Pozelimab, a Human Monoclonal Antibody Against Complement Factor C5, Provided Inhibition of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

(2021) Jun-Ho Jang et al.   BLOOD

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5

(2020) Adrianna Latuszek et al.   PLoS One

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

(2019) Kishor Devalaraja-Narashimha et al.   BLOOD

CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis

(2017) Ahmet Ozen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paroxysmal nocturnal haemoglobinuria

(2017) Anita Hill et al.   Nature Reviews Disease Primers